United States Patent 6,699,503 Hydrogel-Forming Sustained-Release Oral Compositions: Claim Scope, Legal Enforceability, and Patent Landscape
Executive summary
US 6,699,503 claims a narrow but composition-defining technology for hydrogel-forming sustained-release oral preparations with a gelation index ≥70%, built around (i) a high-solubility PEG/PEO component capped at ≤80% by weight, (ii) a viscosity-threshold hydrogel-forming polymer at ≥10% and up to 95% by weight with a minimum mass per unit of ≥70 mg, and (iii) a drug loading cap of ≤85% by weight. The claims are drafted to enforce specificity through functional/quantitative parameters (gelation index, PEG solubility expressed as water volume per gram, polymer viscosity at defined conditions, and mass-per-preparation). This creates a clear claim boundary for product design-around via excipient substitution, PEG/PEO viscosity or solubility selection, gelation-index avoidance, or lowering per-unit polymer mass.
What patents protect hydrogel-forming sustained-release oral preparations with gelation index ≥70%?
Direct claim coverage in US 6,699,503 (core technology perimeter)
US 6,699,503 is an enabling composition claim set focused on a specific sustained-release oral dosage architecture defined by gelation performance and excipient physical properties. The independent features in both claims are:
-
Gelation performance constraint
- “Hydrogel-forming sustained-release oral preparation” with gelation index of 70% or more.
-
Drug loading
- A drug present at not more than 85% by weight of the total preparation.
-
PEG/PEO component defined by solubility
- A polyethylene glycol with solubility such that ≤5 mL of water is required to dissolve 1 g of PEG.
- Amount of PEG: 5 to 80% by weight.
-
Hydrogel-forming polymer defined by viscosity and minimum dose
- Polymer viscosity: ≥1000 cps, measured at 1% concentration in water at 25°C.
- Amount: 10 to 95% by weight.
- Additional per-preparation requirement: ≥70 mg per one preparation.
Claim 1 vs Claim 2 (substitution of PEG/PEO viscosity-defined polymer identity)
- Claim 1: uses PEG for the solubility-defined excipient and a separate “hydrogel-forming polymer” defined by viscosity.
- Claim 2: replaces the “hydrogel-forming polymer” with polyethylene oxide that also meets the viscosity threshold (≥1000 cps at 1% in water at 25°C) while keeping the solubility-defined PEG excipient.
Immediate claim implication: the patent targets a dual-role polymer/excipient system where gelation relies on a high-viscosity hydrogel-forming polymer and sustained release is supported by the solubility-select PEG/PEO fraction. The claim language is structured to block straightforward substitutions that change the measured viscosity or solubility properties.
How are the quantitative parameters used to narrow scope in practice?
The claims use measurable, testable numeric boundaries that drive both infringement analysis and design-around strategy.
Key thresholds and their legal/technical effect
- Gelation index ≥70%
- This is the outer functional gate. Even with all other component criteria met, a product that tests below 70% on the claimed gelation-index method would not fall within the literal claim scope.
- PEG solubility expressed as “≤5 mL water per 1 g PEG”
- This is a proxy for PEG molecular weight/grade and crystallinity/amorphous behavior. Lower solubility PEG variants can fall outside the “not more than 5 mL” boundary.
- Hydrogel-forming polymer viscosity ≥1000 cps (1% in water at 25°C)
- This eliminates low-viscosity polymers at the claimed concentration and condition. It also limits excipient selection and requires consistent measurement across accused products.
- Per-unit minimum polymer mass ≥70 mg
- This blocks formulations with the correct percentages but lower-unit dosing or different unit scale that fails the mass floor.
Drug loading cap ≤85% by weight
- This is unusually explicit for a “drug-agnostic” formulation patent. It prevents very drug-heavy matrices. It also impacts combination products where API loading is high.
What is the claim scope of US 6,699,503 and where are the infringement fault lines?
Literal infringement fault lines
To be within scope, the accused product must satisfy all elements:
- Type and dosage form
- “Hydrogel-forming sustained-release oral preparation.” If the product does not form a hydrogel in the relevant environment or is not sustained-release, it risks exclusion. But most disputes will center on the quantitative elements.
- Gelation index
- Must be ≥70% by the patent’s gelation-index test method (method identity and conditions matter in practice).
- Composition constraints
- Drug ≤85% w/w.
- PEG component is solubility-defined: 1 g dissolves in ≤5 mL water.
- PEG amount 5 to 80% w/w.
- Hydrogel-forming polymer is viscosity-defined at ≥1000 cps (1% at 25°C).
- Polymer amount 10 to 95% w/w and per-unit mass ≥70 mg.
Functional boundary strength
Because several limitations are numeric and physical-property-based (solubility volume, viscosity, gelation index), infringement is likely to hinge on formulation testing and material-grade matching. Courts treat such limitations as claim elements, not mere descriptors.
Does claim 1 cover PEG as both excipient roles, or only as solubility-defined PEG?
Claim 1 separately recites:
- PEG defined by solubility and amount.
- A hydrogel-forming polymer defined by viscosity and amount.
So even if the same chemical family could be used, the claim structure implies distinct compositional components (even if they are related). If an accused product uses a single polyethylene species that simultaneously satisfies solubility and viscosity requirements, analysis could turn on whether it still meets the claim’s separate recitations as “PEG” and “hydrogel-forming polymer.” Practically, litigants will argue whether one material can fulfill both limitations and whether the claim requires distinct ingredients.
How strong is the patent estate for US 6,699,503 hydrogel-forming sustained-release oral formulations?
Strength drivers
- Numerical constraints reduce overbreadth and improve enforceability by tying coverage to measurable properties.
- Drug-agnostic framing (“a drug”) broadens the API coverage but remains bounded by excipient constraints.
Strength limiters
- Numeric thresholds can enable straightforward design-around if alternative excipient grades can be selected to reduce gelation index below 70% or shift viscosity below 1000 cps at the stated test conditions, or change PEG solubility behavior beyond the ≤5 mL rule.
- The “gelation index” limitation is a frequent litigation focus: test method identity and reproducibility can become central.
Estate reality check (what the landscape typically looks like)
Without the patent’s bibliographic metadata in the prompt (filing date, assignee, continuation status) it is not possible to enumerate the exact family and prosecution history, or map the complete citation-based network around US 6,699,503 with precision. A complete landscape requires those documents.
Given only the claim text, the enforceable estate characterization is limited to the claim architecture itself: it is a composition claim with performance gates, which typically motivates (i) competitor formulation variants and (ii) continuation/divisional filing patterns around the same gelation index window, PEG/PEO solubility boundary, and viscosity threshold.
When does US 6,699,503 lose exclusivity? What expiration dates apply in the US?
This cannot be computed or stated accurately from the claim text alone. US patent term depends on filing date and potential PTA/PTE adjustments. Without the patent’s filing date and any adjustments, the exclusivity timeline cannot be established.
What formulation patents and follow-on applications commonly overlap with US 6,699,503?
Typical overlapping subject matter in hydrogel-forming sustained-release oral space
Even without the specific family members, the most common neighbor patents (by claim style) for this technology cluster usually address:
- gelation index optimization ranges around ≥70%
- PEG/PEO grade selection to hit or avoid ≤5 mL per gram solubility behavior
- polymer molecular weight/viscosity tuning at 1% in water at 25°C
- per-unit mass effects for sustained release (matching ≥70 mg)
- alternative hydrogel-forming polymer chemistries that either meet viscosity thresholds or purposely miss them
- different sustained-release architectures that form gels but fail the claimed gelation-index metric
Design-around leverage points derived from the claim language
- Use PEG grade that requires >5 mL water per gram to dissolve at relevant conditions.
- Use a hydrogel polymer with viscosity <1000 cps at 1% in water, 25°C.
- Adjust polymer loading so the unit dose polymer mass is <70 mg.
- Reduce gelation index to <70% via polymer selection or ratio change.
- Increase drug loading above 85% by weight if the product can still be sustained-release, though in practice this can conflict with the hydrogel matrix.
Which companies are challenging or licensing hydrogel-forming sustained-release oral PEG/PEO systems?
Not determinable from the provided information. A company-by-company litigation or licensing map requires case captions, Orange Book entries, or assignment/litigation records tied to US 6,699,503.
What is the Orange Book status of US 6,699,503-related products?
Not determinable from the provided information because Orange Book listing requires the associated FDA-approved drug product(s), NDA/ANDA/BLA identifiers, and the patent-to-product linkage.
What patent litigation affects US 6,699,503? Are there Paragraph IV challenges?
Not determinable from the provided information. Litigation and Paragraph IV events depend on identification of the related approved drug and any Orange Book-linked patents.
How does US 6,699,503 compare with competing hydrogel sustained-release patents (composition vs method)?
Comparison axis that matters for enforcement
- US 6,699,503 is a composition claim with excipient and performance thresholds.
- Many competitor filings in sustained-release hydrogel tech focus on:
- method-of-manufacture,
- drug release kinetics rather than gelation index,
- alternative polymer chemistry without the explicit solubility-per-gram/viscosity-at-condition style limits.
Practical competitive distinction
- Composition-performance patents force generics to match specific material properties and formulation outcomes, not just release profile.
- Method or device claims often create a narrower infringement route but can be harder to enforce across manufacturing sites.
Generic entry risks for hydrogel-forming sustained-release oral formulations with gelation index ≥70%
Generic risk posture implied by the claim
- If an accused generic can be formulated to fall below one numeric gate, risk drops sharply.
- If the generic is constrained to reproduce the same excipient grades and unit mass due to bioequivalence constraints, risk increases because the claim’s thresholds are measurable and may naturally be matched if the original product used similar gel-forming excipient systems.
What generic designers typically do against threshold claims
- Switch PEG/PEO grades to alter solubility and viscosity behavior.
- Rebalance ratios to shift gelation index.
- Adjust unit mass and polymer content below the per-preparation floor.
Regulatory pathway impact: Does the patent affect NDA, ANDA, or 505(b)(2) filings?
Not determinable from the provided information because the regulatory impact depends on which specific FDA-approved product is covered by US 6,699,503 and how it is listed in the Orange Book.
Key Takeaways
- US 6,699,503 is a composition patent enforcing hydrogel performance and excipient physical properties through four quantitative gates: gelation index ≥70%, PEG solubility ≤5 mL water per gram, hydrogel polymer viscosity ≥1000 cps at 1%/25°C, and polymer mass ≥70 mg per unit, plus drug loading ≤85% w/w and excipient ratio windows.
- Claim 1 and claim 2 differ by whether the viscosity-defined hydrogel-forming component is described as a generic “hydrogel-forming polymer” or specifically as polyethylene oxide meeting the viscosity threshold.
- The claim architecture makes infringement and validity arguments highly test-dependent; design-around is most feasible through excipient grade selection and property engineering to miss one numeric threshold.
- Expiration, Orange Book status, litigation, and competitor-specific risk cannot be determined from claim text alone.
FAQs
- Can one polymer ingredient satisfy both the solubility-defined PEG and viscosity-defined hydrogel polymer limitations in the same formulation?
- How do gelation-index testing variability and method selection affect infringement analysis for gelation index ≥70% claims?
- What formulation changes most reliably reduce gelation index below 70% while preserving sustained release?
- If a generic matches drug identity and dosage form, does failing a single quantitative excipient threshold avoid literal infringement?
- Do viscosity thresholds measured at 1% concentration in water at 25°C translate directly to in vivo behavior arguments during claim construction?
References
- US Patent 6,699,503. (Claim text provided).
